Olema Pharmaceuticals, Inc. (OLMA)
OLMA Stock Price Chart
|Net Income (ttm)||-14.88M|
|Trading Day||November 30|
|Day's Range||49.21 - 52.01|
|52-Week Range||47.11 - 52.78|
OLMA Stock News
Olema Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and...
SAN FRANCISCO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Olema Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead program is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of metastatic or locally advanced, ER-positive, and human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
|IPO Date |
Nov 19, 2020
|Stock Exchange |
|Ticker Symbol |